Aqeel A. Fatmi was appointed Director of Elite Pharmaceuticals Inc /Nv/, effective October 28, 2026. As of November 4, 2026, Elite Pharmaceuticals Inc /Nv/ has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 3, 2026, naming 1 appointment (Form 8-K, November 3, 2026).
Sell to companies like Elite Pharmaceuticals Inc /Nv/? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Elite Pharmaceuticals Inc /Nv/ reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-03. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Elite Pharmaceuticals Inc /Nv/ files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-03 | In | Director | 2026-10-28 | 8-K, 2026-11-03 |
Selling to them or working with them? See who runs Elite Pharmaceuticals Inc /Nv/ now and the warning signs.
Free to see. No signup.
Watch Elite Pharmaceuticals Inc /Nv/
Get an email when Elite Pharmaceuticals Inc /Nv/ files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Elite Pharmaceuticals Inc /Nv/?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Elite Pharmaceuticals Inc /Nv/: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Elite Pharmaceuticals Inc /Nv/ covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Elite Pharmaceuticals Inc /Nv/, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Aqeel A. Fatmi, appointed, effective 2026-10-28 (filed 2026-11-03).
New leaders reset buying decisions — get the Full Report on Elite Pharmaceuticals Inc /Nv/: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Elite Pharmaceuticals Inc /Nv/, with the record behind each one.
Find candidates like Director at Elite Pharmaceuticals Inc /Nv/Every change, in the filing's words
Appointed: Aqeel A. Fatmi, Director, effective 2026-10-28
On October 28, 2026, the Board of Directors (the "Board") of Elite Pharmaceuticals, Inc. (the "Company") increased the size of the Board from four to six directors and unanimously elected Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq., as Class II and Class I directors of the Company, respectively, effective October 28, 2026.
- Each of Dr. Fatmi and Mr. LaRocca will serve until the Company's next annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.
- The Board has not yet named either director to a committee of the Board or determined the committee or committees to which they will be named.
- In connection with their respective elections to the Board, Dr. Fatmi and Mr. LaRocca will receive compensation in the same manner as the Board's other non-management directors.
- Since March 2016, he has served as an independent strategic and technical advisor to pharmaceutical companies and investors.
- His advisory and consulting engagements during the past ten years have included Tennenbaum Capital Partners, LLC/BlackRock Inc. (operating advisor, June 2017 to August 2026), Strides Pharma Inc. (consultant and advisor, April 2017 to April 2026), Aspire Pharmaceuticals, Inc. (consultant and advisor, June 2017 to October 2023) and Sofgen Pharma S.A. (consultant, July 2022 to October 2024).
- He served as a non-executive independent board advisor to Novasep SAS from May 2019 to March 2022.
Tools for this story
Each opens in a new tab, filled in for Elite Pharmaceuticals Inc /Nv/. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.